Infinimmune, Merck enter into antibody discovery pact
Published on March 31, 2026.
Biotech firm Infinimmune has entered into a deal with Merck (MRK.N) to discover and develop multiple antibodies for various undisclosed disease targets. The agreement could be worth up to $838 million in milestone payments. The companies did not disclose the disease targets chosen. Infinamic is also developing its own early-stage medicines for eczema and other diseases.
Related Articles
NTSB raises questions on driver assistance systems, lack of regulations
The National Transportation Safety Board criticizes the lack of regulations and claims about driver assistance systems, while investigating two fatal crashes involving Ford Motor's BlueCruise.
276-Unit Mall Redevelopment In Flood-Prone Area Approved In Raritan
The Raritan Borough Planning Board approved a 276-unit housing development on a flood-prone site, including market-rate units and affordable housing.
US FDA is expected to lift restriction on certain peptides, NYT reports
The US FDA is expected to lift a restriction on certain peptides, allowing companies to produce and sell products without restriction.